Stephens & Co. Reiterates Equal-Weight on Anika Therapeutics, Maintains $24 Price Target
Portfolio Pulse from Benzinga Newsdesk
Stephens & Co. analyst George Sellers has reiterated an Equal-Weight rating on Anika Therapeutics (NASDAQ:ANIK) and maintained a $24 price target.
May 29, 2024 | 1:21 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Stephens & Co. analyst George Sellers has reiterated an Equal-Weight rating on Anika Therapeutics and maintained a $24 price target.
The reiteration of an Equal-Weight rating and maintenance of the $24 price target suggests a neutral outlook from the analyst. This is unlikely to cause significant short-term price movement.
CONFIDENCE 90
IMPORTANCE 60
RELEVANCE 100